NWBO (Northwest Biotherapeutics) EPS (Basic): $-0.03 (TTM As of Mar. 2026)

What is Northwest Biotherapeutics EPS (Basic)?

Northwest Biotherapeutics NWBO -0.58% 17 EPS (Basic) is $-0.03 as of Mar. 2026. GuruFocus rates NWBO with a GF Score™ of 17/100. The stock has 5 warning signs investors should review.

Northwest Biotherapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.03.

Northwest Biotherapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.03.

Northwest Biotherapeutics's EPS without NRI for the three months ended in Mar. 2026 was $-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.04.

During the past 3 years, the average EPS without NRI Growth Rate was 10.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 22.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 25.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Northwest Biotherapeutics's highest 3-Year average EPS without NRI Growth Rate was 64.20% per year. The lowest was -12.50% per year. And the median was 29.60% per year.

Northwest Biotherapeutics (OTCPK:NWBO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Northwest Biotherapeutics EPS (Basic) Related Terms

Northwest Biotherapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Northwest Biotherapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northwest Biotherapeutics EPS (Basic) Chart

Northwest Biotherapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

0.21

-0.10

-0.06

-0.07

-0.04

Northwest Biotherapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															-0.01	-0.01	-0.02	0.00	0.00

17GF Score

Northwest Biotherapeutics Inc NWBO

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Northwest Biotherapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Northwest Biotherapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-60.162	-	0)	/	1456.663
	=	-0.04

Northwest Biotherapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.069	-	0)	/	1584.843
	=	-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of $-0.03 mean?

Northwest Biotherapeutics (NWBO) has a EPS (Basic) of $-0.03 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Northwest Biotherapeutics and its competitors.

Is Northwest Biotherapeutics' EPS (Basic) too high?

Northwest Biotherapeutics' current EPS (Basic) is $-0.03. Overall, Northwest Biotherapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.

How does Northwest Biotherapeutics' EPS (Basic) compare to PROK and AVIR?

Northwest Biotherapeutics' EPS (Basic) of $-0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Northwest Biotherapeutics and its competitors. Northwest Biotherapeutics's current EPS (Basic) is $-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Northwest Biotherapeutics stock overvalued right now?

Northwest Biotherapeutics (NWBO) has a current EPS (Basic) of $-0.03. The current EPS (Basic) is $-0.03. Northwest Biotherapeutics' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Northwest Biotherapeutics (NWBO), the current EPS (Basic) is $-0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Northwest Biotherapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies PROK AVIR IMRX PALI PBYI VSTM GLSI LRMR RGNX ENTA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges NBYB:Germany

Address 4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website https://www.nwbio.com

Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.

17GF Score

Get the complete analysis for NWBO

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19

Price

View NWBO Analysis

See EPS (Basic) data for all stocks →